Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: targetedmoab who wrote (8341)	11/25/2009 10:05:26 PM
From: stockdoc77	of 63324

At least two patients post their experiences on blogs. It is public knowledge, albeit a bit hard to find. The NDA would apply to investigators, but not to the patients or ancillary staff (i.e. a treating nurse in a hospital). HIPAA laws do require health care providers to maintain confidentiality, but that is an obligation we all have to our patients, not derived from any trial participation agreements. AS long as you don't disclose the patient's name, and simply discuss the clinical outcome, it is not a HIPAA violation, no more so than if I were to post that I have a patient who is currently responding to steroids for his lung injury. The current phase 1 trial is also non-blinded, it is open label and I'm not sure to what extent even the investigators are barred from speaking about results. Pennington gave a long set remarks about the first two patients as part of IMMU RD day last year, and this was before any data had been peer reviewed and released in a public form. BTW, I am a physician and as far as I know Idaho runs a ranch in Idaho.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next